- REPAIR, an $ 165 m impact fund to compat antimicrobial resistance to invest in Research and early-stage development
- Lloyd Payne, EVP Anti-infectives from Evotec will join the scientific selection Board of REPAIR
Hamburg, Germany, 28 February 2018: According to a press release published today by Novo Holdings, a new fund has been launched focused on new approaches to fight against antimicrobial resistance.
The fund called REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) will focus on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 12 families of bacteria that pose the greatest threat to human health. It is commissioned by the Novo Nordisk Foundation with a total budget of $ 165 million to invest in organisations involved in discovery and early-stage development of therapies to combat antimicrobial resistance.
The projects will be selected through an investment process with the support of a highly qualified Scientific Selection Board comprising 10 world-class experts. The Scientific Selection Board is comprised of Novo investment partners and anti-infectives industry veterans and will review and recommend programmes for subsequent investment. This Board includes Dr Lloyd Payne, Executive Vice President, Anti-infectives of Evotec. Lloyd has more than 20 years’ experience in the biopharmaceutical sector, leading programs in the infectious disease, inflammation, and oncology therapeutic areas. He was also the founding CEO of Euprotec, a specialised anti-infective CRO which was acquired by Evotec in 2014.
The first round of investments dedicated to European companies will start in April 2018 and non-confidential presentations can be sent until 15 May 2018. The first investments are expected by the end of 2018. A second round of investments focusing on United States companies will start in the fall 2018.
For more details about the investment process, see www.repair-impact-fund.com/investment-process.
Further information Aleks Engel, Partner, Novo Holdings, +45 3067 4796, firstname.lastname@example.org
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.